Reaction
Chronic Myelomonocytic Leukaemia reporting signals
As of the last recalculation, Chronic Myelomonocytic Leukaemia appears in 657 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is AZACITIDINE (PRR 111.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Azacitidine | 90 | 111.2 | 111.5 |
| Azacitidine For | 36 | 66.3 | 66.4 |
| Romiplostim | 21 | 45.6 | 45.7 |
| Avapritinib | 15 | 40.1 | 40.2 |
| Hydroxyurea | 24 | 37.3 | 37.3 |
| Melphalan Hydrochloride | 20 | 26.0 | 26.1 |
| Melphalan | 18 | 25.7 | 25.8 |
| Daspone | 7 | 23.0 | 23.0 |
| Dapsone Gel, 5% | 7 | 23.0 | 23.0 |
| Eltrombopag Olamine | 16 | 22.5 | 22.5 |
| Imatinib | 12 | 21.9 | 22.0 |
| Dapsone | 7 | 21.0 | 21.0 |
| Deferasirox | 13 | 15.8 | 15.8 |
| Gemcitabine | 17 | 14.0 | 14.0 |
| Bendamustine Hydrochloride | 5 | 13.3 | 13.3 |
| Bosutinib | 3 | 10.6 | 10.6 |
| Vemurafenib | 4 | 10.6 | 10.6 |
| Venetoclax | 18 | 9.5 | 9.5 |